{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T14:12:15Z","timestamp":1787407935500,"version":"build-2736575974"},"reference-count":12,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Hematology"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Hereditary haemorrhagic telangiectasia (HHT) is a genetic vascular disorder characterised by telangiectases, which cause nasal and gastrointestinal (GI) bleeding, and visceral arteriovenous malformations. Since 2012 bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor, has been a promising treatment for HHT-related bleeding and was evaluated in the phase II BABH study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To follow and describe evolution and treatments of patients with HHT post-BABH study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>This study is a 1-year, multi-centre descriptive study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We collected clinical (nose and GI bleeding, red blood cell transfusions) and biological (haemoglobin and ferritin levels) data and treatment information.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Of 22 patients included across 4 centers, 15 received bevacizumab. Among them, 12 (86%) had a &gt;50% decrease in the number of RBC units transfused 3 months post-treatment. Mean haemoglobin levels increased from 83.08 to 105.98 g\/L.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Bevacizumab effectively reduces RBC transfusions and is efficient for treating severe bleeding in patients with HHT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration:<\/jats:title>\n                    <jats:p>This trial was registered with the ClinicalTrials.gov Identifier #NCT06039124.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20406207241300828","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T01:24:02Z","timestamp":1744680242000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["BEST study: one-year descriptive follow-up of bevacizumab treatment in hereditary haemorrhagic telangiectasia post-BABH interventional study"],"prefix":"10.1177","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8834-5526","authenticated-orcid":false,"given":"Sophie","family":"Dupuis-Girod","sequence":"first","affiliation":[{"name":"Hospices Civils de Lyon, H\u00f4pital Femme-M\u00e8re-Enfants, Service de G\u00e9n\u00e9tique et centre de R\u00e9f\u00e9rence de la maladie de Rendu-Osler, 59 Bd Pinel, Bron 69677, France"},{"name":"Laboratory Biology of Cancer and Infection, University Grenoble Alpes, Inserm, CEA, Grenoble, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyne","family":"Decullier","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, P\u00f4le Sant\u00e9 Publique, Lyon, France"},{"name":"Facult\u00e9 de m\u00e9decine, Universit\u00e9 Lyon 1, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Rivi\u00e8re","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Interne A, Centre Hospitalier Universitaire, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Lavigne","sequence":"additional","affiliation":[{"name":"Service de m\u00e9decine interne-Immunologie clinique, CHU d\u2019Angers, Angers Cedex 09, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Grobost","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Interne CHU Estaing, Clermont-Ferrand University Hospital, Clermont-Ferrand, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Leguy-Seguin","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Interne 1, CHU Francois Mitterrand, Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Maillard","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Interne et Immunologie Clinique, CHU Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Chinet","sequence":"additional","affiliation":[{"name":"Centre Rendu-Osler, H\u00f4pital Ambroise Par\u00e9, Assistance Publique-H\u00f4pitaux de Paris, Universit\u00e9 de Versailles SQY, Boulogne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Emmanuelle","family":"Fargeton","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, H\u00f4pital Femme-M\u00e8re-Enfants, Centre de R\u00e9f\u00e9rence de la maladie de Rendu-Osler, Bron, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Guilhem","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, H\u00f4pital Femme-M\u00e8re-Enfants, Service de G\u00e9n\u00e9tique et centre de R\u00e9f\u00e9rence de la maladie de Rendu-Osler, Bron, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Hermann","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, H\u00f4pital, Service d\u2019ORL, H\u00f4pital E. Herriot, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,4,14]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI176379"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13714"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13713"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.250"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1024\/0301-1526\/a000253"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.2500\/ar.2014.5.0091"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0188943"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2017.11.013"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.261859"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2022.104575"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0228486"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-67144-4_12"}],"container-title":["Therapeutic Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207241300828","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20406207241300828","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207241300828","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:17:27Z","timestamp":1777591047000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20406207241300828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,14]]},"references-count":12,"alternative-id":["10.1177\/20406207241300828"],"URL":"https:\/\/doi.org\/10.1177\/20406207241300828","relation":{},"ISSN":["2040-6207","2040-6215"],"issn-type":[{"value":"2040-6207","type":"print"},{"value":"2040-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,14]]},"article-number":"20406207241300828"}}